William N. Woods Appointed Chief Financial Officer
EDMONTON, Feb. 27 /CNW/ - CardioMetabolics(TM) inc. today announced that
it has appointed Yves Rosconi, L. Pharm., MBA to its Board of Directors and
William N. Woods, CMA to the position of Chief Financial Officer.
Yves Rosconi is currently the President and Chief Executive Officer of
Theratechnologies. He began his career with Abbott Laboratories and went on to
spend 21 years with Rhône-Poulenc Rorer (now Sanofi-Aventis) in Canada and
Australia with increasing responsibilities, ultimately becoming President and
General Manager of Canadian operations. After leaving Rhône-Poulenc Rorer, he
spent the next two years as Chief Operating Officer of AEterna Laboratories
before joining Paris-based Aventis as Senior Vice President, responsible for
Africa and the Middle East.
"Appointing Mr. Rosconi to our Board of Directors demonstrates our
commitment to recruiting knowledgeable and experienced professionals to our
team," said Dr. Larry Ohlhauser, Chairman of the CardioMetabolics Board of
Directors. "Mr. Rosconi's extensive experience and expertise in piloting a
drug candidate through a successful late stage trial and within a large
pharmaceutical organization will be invaluable as we near completion of our
Phase II trial for DCA i.v., plan initiation of our Phase III trial, and
continue toward the commercialization of this exciting candidate."
William N. Woods is a Certified Management Accountant with more than
10 years experience as a senior financial executive. He most recently served
as Vice-President Finance for a ground transportation company. Mr. Woods'
experience includes financial operations, strategic management and leadership
within a variety of business models in different sectors, including mining,
manufacturing and transportation.
Edmonton-based CardioMetabolics inc. is a privately held, late-stage,
biopharmaceutical company focused on commercializing drug product candidates
in the novel class of energy metabolism agents. The Company has late stage and
earlier stage compounds that target the treatment of cardiovascular disease,
and related metabolic conditions (e.g., diabetes). Cardiovascular disease is
the "number one" cause of death in North America, and each year in the United
States alone, over 700,000 open heart surgeries are conducted.
CardioMetabolics' technology is focused on metabolic modulation, through the
use of dichloroacetate (DCA) and related compounds, which improve energy
production by favoring glucose metabolism.
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.
For further information:
For further information: CardioMetabolics inc., Kimmo Lucas, President
and Chief Executive Officer, Phone: (780) 438-2813, Fax: (780) 438-2874,
E-mail: email@example.com; Investor Relations, Ross Marshall, The
Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax: (416) 815-0080,